Compare · FMS vs SHC
FMS vs SHC
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Sotera Health Company (SHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and SHC operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.36B, about 2.4x SHC ($5.16B).
- Over the past year, FMS is down 18.3% and SHC is up 10.8% - SHC leads by 29.2 points.
- FMS has been more active in the news (5 items in the past 4 weeks vs 2 for SHC).
- SHC has more recent analyst coverage (25 ratings vs 24 for FMS).
- Company
- Fresenius Medical Care AG
- Sotera Health Company
- Price
- $22.16+0.18%
- $17.89-1.00%
- Market cap
- $12.36B
- $5.16B
- 1M return
- +0.43%
- -5.57%
- 1Y return
- -18.35%
- +10.80%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 2
- Recent ratings
- 24
- 25
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
- Fresenius Medical downgraded by Berenberg
- Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
Latest SHC
- Sotera Health downgraded by Analyst with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Executive Chairman Petras Michael B. Jr. sold $21,174,786 worth of shares (1,144,515 units at $18.50), decreasing direct ownership by 43% to 397,912 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Leadership Update
- President of Sterigenics Rutz Michael P sold $2,825,250 worth of shares (150,000 units at $18.84), decreasing direct ownership by 31% to 334,279 units (SEC Form 4)
- Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,316 shares, decreasing direct ownership by 5% to 217,304 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by Sotera Health Company
- SEC Form 10-Q filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits